3 Best Biotech Acquisitions of 2018 (So Far)

There's room for debate, of course. But in my view, three deals especially stand out. Here's why I rank Celgene's (NASDAQ:CELG) buyout of Juno Therapeutics, Novartis' (NYSE:NVS)acquisition of AveXis, and Roche's (NASDAQOTH:RHHBY) purchase of Foundation Medicine(NASDAQ:FMI) as the best biotech acquisitions of 2018 (so far).